In a non-invasive and rapid salivary screening test, GAPDH could be included in a damage-associated molecular pattern, which could find clinical applications to recognize individuals early on who are at risk of active PD, thus improving the clinical management and treatment of periodontal patients. This evidence concerns the gene GAPDH and Parkinson disease.